Breaking News Instant updates and real-time market news.

TGTX

TG Therapeutics

$10.15

0.15 (1.50%)

07:38
08/10/17
08/10
07:38
08/10/17
07:38

TG Therapeutics announces DSBM recommendations in UNITY-NHL Phase 2b Trial

TG Therapeutics announced that the independent Data Safety Monitoring Board, or DSMB, of the UNITY-NHL Phase 2b registration directed trial has successfully completed the first pre-specified interim analysis to evaluate the Overall Response Rate, or ORR, in the cohort enrolling patients with relapsed or refractory Diffuse Large B-cell Lymphoma, or DLBCL, that are not eligible for high-dose chemotherapy or transplant. Upon review of the available ORR data, based on pre-specified efficacy thresholds of ORR, the DSMB recommended the company cease enrollment into the single agent TGR-1202 arm, while continuing enrollment into the TG-1101 + TGR-1202 arm which has demonstrated an acceptable level of efficacy to warrant continued evaluation. Per the UNITY-NHL protocol, the single agent TGR-1202 arm will be replaced by an arm evaluating the triple combination arm of TG-1101, TGR-1202, and bendamustine.

  • 26

    Sep

TGTX TG Therapeutics
$10.15

0.15 (1.50%)

03/13/17
RHCO
03/13/17
NO CHANGE
RHCO
TG Therapeutics data 'highly positive,' says SunTrust
SunTrust analyst Yatin Suneja says that the data on TG's CD20 antibody, TG-1101, was "highly positive." The analyst expects additional data on the drug due out in June to support its approval, and he thinks that the company has multiple potential positive turning points over the next 6-18 months. He raised his price target on the shares to $28 from $26 and keeps a Buy rating.
04/25/17
JEFF
04/25/17
INITIATION
Target $23
JEFF
Buy
TG Therapeutics initiated with a Buy at Jefferies
Jefferies analyst Matthew Andrews started TG Therapeutics with a Buy rating and $23 price target. The company is undervalued based on the long-term promise of ublituximab, TGR-1202 and TG-1303 in B-cell cancers and multiple sclerosis, the analyst contends.
06/05/17
JEFF
06/05/17
NO CHANGE
Target $23
JEFF
Buy
TG Therapeutics data supportive of approval, says Jefferies
Jefferies analyst Matthew Andrews believes the data announced over the weekend by TG Therapeutics for TG-1101 plus ibrutinib in patients with previously treated high risk Chronic Lymphocytic Leukemia are supportive of approval. The hazard ratio of 0.56 is encouraging, Andrews tells investors in a research note. He views TG shares as undervalued and keeps a Buy rating on the name with a $23 price target.
06/16/17
RHCO
06/16/17
NO CHANGE
RHCO
TG Therapeutics data encouraging, says SunTrust
SunTrust analyst Yatin Suneja says that the follow-up Phase I/Ib data on TG's triplet combination in DLCL and FL is "encouraging." The analyst thinks that the data shows that the combination "is highly active and relatively well-tolerated." Suneja is encouraged by the results and expects an upcoming pre-BLA meeting with the FDA to be positive. The analyst keeps a $28 price target and a Buy rating on the shares.

TODAY'S FREE FLY STORIES

ACOR

Acorda Therapeutics

$17.80

0.55 (3.19%)

10:25
11/20/17
11/20
10:25
11/20/17
10:25
Recommendations
Acorda Therapeutics analyst commentary  »

Acorda discontinuation of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

10:25
11/20/17
11/20
10:25
11/20/17
10:25
General news
U.S. leading index surged 1.2% in October to 130.4 »

U.S. leading index surged…

MACK

Merrimack

$11.75

0.1 (0.86%)

10:25
11/20/17
11/20
10:25
11/20/17
10:25
Conference/Events
Merrimack participates in a conference call with JPMorgan »

JPMorgan SMid Biotech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

DBVT

DBV Technologies

$23.43

0.63 (2.76%)

10:20
11/20/17
11/20
10:20
11/20/17
10:20
Recommendations
DBV Technologies analyst commentary  »

Jefferies still sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$188.63

3.502 (1.89%)

10:20
11/20/17
11/20
10:20
11/20/17
10:20
Options
Active trading in Alibaba as shares see relative strength »

Active trading in Alibaba…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:20
11/20/17
11/20
10:20
11/20/17
10:20
General news
Treasury Action: long yields cooled off from highs »

Treasury Action: long…

RRC

Range Resources

$17.53

-0.5 (-2.77%)

10:19
11/20/17
11/20
10:19
11/20/17
10:19
Technical Analysis
Technical View: Range Resources drops, levels to watch »

The shares are down over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:17
11/20/17
11/20
10:17
11/20/17
10:17
General news
Market begins holiday-shortened week on positive note »

Stock futures improved…

$NSD

NASDAQ Market Internals

10:17
11/20/17
11/20
10:17
11/20/17
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

10:16
11/20/17
11/20
10:16
11/20/17
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
11/20/17
11/20
10:15
11/20/17
10:15
General news
FX Action: The dollar »

FX Action: The dollar…

MRO

Marathon Oil

$14.70

-0.3537 (-2.35%)

10:14
11/20/17
11/20
10:14
11/20/17
10:14
Technical Analysis
Technical View: Marathon Oil drops, levels to watch »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

DVN

Devon Energy

$37.66

-1.02 (-2.64%)

10:10
11/20/17
11/20
10:10
11/20/17
10:10
Options
Bullish option activity in Devon Energy as shares fall »

Bullish option activity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACOR

Acorda Therapeutics

$17.80

0.55 (3.19%)

10:09
11/20/17
11/20
10:09
11/20/17
10:09
Hot Stocks
Acorda drops Parkinson's drug less than a week after reporting deaths in study »

Shares of Acorda…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

DBVT

DBV Technologies

$23.43

0.63 (2.76%)

10:07
11/20/17
11/20
10:07
11/20/17
10:07
Recommendations
DBV Technologies analyst commentary  »

DBV safety study data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPLO

Diplomat Pharmacy

$14.99

-0.015 (-0.10%)

10:05
11/20/17
11/20
10:05
11/20/17
10:05
Conference/Events
Diplomat Pharmacy management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

  • 29

    Nov

10:01
11/20/17
11/20
10:01
11/20/17
10:01
General news
Leading Indicators data reported »

October Leading…

GD

General Dynamics

$198.15

0.38 (0.19%)

10:01
11/20/17
11/20
10:01
11/20/17
10:01
Hot Stocks
General Dynamics unit awarded $52M U.S. Army contract »

General Dynamics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIAB

Viacom

$26.15

2.46 (10.38%)

10:00
11/20/17
11/20
10:00
11/20/17
10:00
Technical Analysis
Technical View: Viacom rises, analyst action »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSA

Comcast

$36.16

-0.91 (-2.45%)

10:00
11/20/17
11/20
10:00
11/20/17
10:00
Options
Call buying in Comcast »

Call buying in Comcast.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:00
11/20/17
11/20
10:00
11/20/17
10:00
General news
Bund/T-note spread widening is pushing -200 bp »

Bund/T-note spread…

HON

Honeywell

$147.08

0.59 (0.40%)

09:58
11/20/17
11/20
09:58
11/20/17
09:58
Hot Stocks
Honeywell to provide cryogenic gas processing plant to EagleClaw Midstream »

Honeywell announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

URBN

Urban Outfitters

$27.90

1.45 (5.48%)

09:55
11/20/17
11/20
09:55
11/20/17
09:55
Options
Urban Outfitters put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

FTR

Frontier Communications

$6.96

0.3 (4.50%)

, DLPH

Delphi

$102.23

3.53 (3.58%)

09:55
11/20/17
11/20
09:55
11/20/17
09:55
Options
Early notable gainers among liquid option names on November 20th »

Notable gainers among…

FTR

Frontier Communications

$6.96

0.3 (4.50%)

DLPH

Delphi

$102.23

3.53 (3.58%)

AVY

Avery Dennison

$109.71

1.4248 (1.32%)

VIAB

Viacom

$26.15

2.46 (10.38%)

WYNN

Wynn Resorts

$152.28

-0.92 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 16

    Jan

ZIOP

Ziopharm

$4.57

-0.17 (-3.59%)

09:55
11/20/17
11/20
09:55
11/20/17
09:55
Conference/Events
Ziopharm to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.